Oral ganciclovir approved for CMV. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Oral ganciclovir approved for CMV. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Common Factor. 1995 Apr;(no 10):21. Unique Identifier : AIDSLINE AIDS/95700375

Abstract: The Food and Drug Administration (FDA) approved the oral form of ganciclovir for maintenance treatment of cytomegalovirus (CMV) retinitis, and it is believed oral ganciclovir will be approved soon for primary prophylaxis of CMV retinitis. The IV form has too many toxicities and is too inconvenient for preventive use. Oral ganciclovir has the same toxicity profile as the IV form. Syntex Corporation, the manufacturer of ganciclovir, has instituted a protocol to allow HIV-positive persons with low CD4 counts to use oral ganciclovir for prophylaxis. The protocol distributes the drug at no cost to the individual. Approval is being sought to use oral ganciclovir to prevent CMV symptoms. Information can be obtained by calling Syntex at (800)569-4630.
Keywords: Administration, Oral Cytomegalovirus Infections/COMPLICATIONS/*DRUG THERAPY Cytomegalovirus Retinitis/COMPLICATIONS/*DRUG THERAPY CD4 Lymphocyte Count Drug Approval Ganciclovir/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Human HIV Infections/COMPLICATIONS Infusions, Intravenous NEWSLETTER ARTICLE

KWDadministration,oralcytomegalovirusinfections/complications/KWDdrugtherapycytomegalovirusretinitis/complications/KWDdrugtherapycd4lymphocytecountdrugapprovalganciclovir/administration&dosage/KWDtherapeuticusehumanhivinfections/complicationsinfusions,intravenousnewsletterarticle
951130
M95B0891

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .